Christine Corrado of Proactive Investors interviewed Dr. Mark Day yesterday at the BIO CEO Investor conference in New York. An excellent summary of the Bioasis xB3 technology, advantages of xB3 over competitors, and some teasers about the upcoming June 2019 FDA meeting and human dose finding trial.
https://youtu.be/JkAIUF3BLnw